Navigation Links
RainDance Appoints Kelly Chief Operating Officer
Date:6/2/2008

LEXINGTON, Mass., June 2 /PRNewswire/ -- RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the appointment of Roch W. Kelly as Chief Operating Officer, effective immediately.

"As RainDance solutions enter commercial development, Mr. Kelly is the ideal leader to establish our manufacturing and financial capabilities," said Chris McNary, President and Chief Executive Officer, RainDance Technologies. "With more than 20 years of experience in life sciences, he brings a proven record of successfully implementing the process and controls in these critical areas to meet the anticipated demand for our products."

Kelly joins RainDance from Synarc, Inc., where he was Vice President, Clinical Operations. Under his leadership, the operational team rapidly implemented new processes and systems that achieved a 25% improvement in efficiency. Previous positions included Chief Operating Officer and Chief Financial Officer at Protedyne, Inc., and Vice President, Clinical Operations and Worldwide Business, at PAREXEL International. He also served as Executive Director of Manufacturing Operations at Chiron Diagnostics. Kelly received a Bachelor of Science degree in finance from Miami (Ohio) University and a Master of Business Administration degree from Syracuse University.

About RainDance Technologies, Inc.

RainDance Technologies is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company's exciting new technology enable researchers to design experiments in ways that were previously unaffordable or unimaginable.

The company's technology produces picoliter-sized droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.

RainDance's initial application will focus on the targeted resequencing of the human genome -- one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board. RainDance advisers include three Nobel Prize winners: Jean-Marie Lehn (Chemistry, 1987), Aaron Klug (Chemistry, 2002), and Richard Roberts (Physiology or Medicine, 1993), as well as Sir Gregory Winter, joint head of the British Division of Protein and Nucleic Acids Chemistry at the Medical Research Council's Laboratory of Molecular Biology in Cambridge.

For more information, please visit http://www.raindancetechnologies.com.


'/>"/>
SOURCE RainDance Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. RainDance Announces Company Relocation and Manufacturing Startup
2. RainDance Appoints Becker Chief Commercial Officer
3. RainDance Technologies Appoints McNary President and CEO
4. IntegriChain Appoints John Bailye to Its Board of Directors
5. Trius Appoints Paul Truex to Board of Directors
6. Pelikan Technologies Appoints Denny Ware to Board of Directors
7. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
8. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
11. Informed Medical Communications Appoints New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
Breaking Biology Technology:
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
Breaking Biology News(10 mins):